EVONIK INDUSTRIES AG WE GO BEYOND TO ENABLE TRANSFORMATION
Company Factbook 2024
Evonik at a glance
€15.3 bn
Sales
€1.7 bn (10.8%)
Adj. EBITDA (margin)
€801 m (48%)
Free Cashflow (conversion)
€1.17 (>6%)
Dividend (yield)
LEADING
BEYOND
CHEMISTRY
Specialty
Additives
Small amount - big effect
Nutrition & Care
Life at heart. Systems in mind. Partners at hand.
Smart Materials
We find solutions for the needs
of today and tomorrow
FY 2023
2 | Evonik Company Factbook | 2024
Evonik well positioned as enabler of transformation
ENSURE HEALTH
& WELL-BEING | DRUG DELIVERY SYSTEMS |
Advanced oral & parenteral | |
drug delivery systems | |
(e.g. mRNA LNP) |
SPECIALTY ADDITIVES
for environmentally-friendly solutions, e.g. water-based artificial leather
CIRCULAR ECONOMY
FIGHT | |
FUTURE MOBILITY | CLIMATE CHANGE |
Lightweight solutions | |
Solutions for hybrid & | |
full battery cars |
ENVIRONMENT & UTILITIES | |
WE GO BEYOND | Membranes for |
biogas separation / hydrogen | |
TO ENABLE | New process catalysts |
TRANSFORMATION | |
SUSTAINABLE NUTRITION |
Circular plastic &
PU additive solutions
Specialty hydrogen peroxides solutions
DRIVE
CIRCULARITY
BIO-BASED SOLUTIONS
Bio-based & fully biodegradable surfactants
Natural active cosmetics ingredients
Omega-3 fatty acids from natural marine algae
Gut health solutions
SAFEGUARD
ECOSYSTEMS
3 | Evonik Company Factbook | 2024
Next Generation Evonik: Our strategy
Three major strategic levers…
Next Generation Portfolio
Exit Performance Materials division
Full focus on three attractive growth divisions
Next Generation Innovation
€1 bn new sales from Innovation Growth Fields by 2025 driven by new products such as membranes or rhamnolipids
… with sustainability fully integrated …
Sustainability
Innovation
Portfolio
… delivering on ambitious targets
ESG Targets1
>50% sales share of
-25% CO2 emission reduction, e.g. via
Financial Targets
Organic growth >4%
Next Generation Culture
Culture
Employee empowerment ("Evonik Tailor Made")
ESG targets integrated into mgmt. compensation
1. Until 2030
4 | Evonik Company Factbook | 2024
EBITDA margin 18-20%
ROCE ~11%
FCF Conversion >40%
Table of contents
- Strategy
- Portfolio
- Sustainability
- Innovation
- Culture
- Divisions
- Specialty Additives
- Nutrition & Care
- Smart Materials
3. Financials
5 | Evonik Company Factbook | 2024
Full focus on three growth divisions and exit from Performance Materials
Specialty | €3.5 bn | |||||
Small amount - | Sales | |||||
Additives | big effect | 19.1% | ||||
Adj. EBITDA Margin | ||||||
Nutrition | Life at heart. | €3.6 bn | ||||
Sales | ||||||
Systems in mind. | ||||||
& Care | ||||||
Partners at hand. | 10.8% | |||||
Adj. EBITDA Margin | ||||||
Smart | We find solutions | €4.5 bn | ||||
Sales | ||||||
for the needs | ||||||
Materials | 12.1% | |||||
of today and tomorrow | ||||||
Adj. EBITDA Margin | ||||||
Exit: Performance Materials
- Division used to consist of three separate businesses:
- Functional Solutions (sold 2023)
- Superabsorber (signed March 2024)
- Performance Intermediates / C4
- Aiming to find new owner/partner for Performance Intermediates as well; division to be ceased thereafter
FY 2023
6 | Evonik Company Factbook | 2024
Active portfolio management on multiple layers
Organic
Business
transformation
Innovation and
product mix
Active M&A
Inorganic
Animal Nutrition
-
Differentiated operating models for specialty and essential nutrition
Hydrogen Peroxide - Changing hydrogen peroxide portfolio towards specially applications
High Performance Polymers
-
Membranes grown from an idea in 2008 to high-double digit million sales in 2023
Care Solutions - Rhamnolipids (bio-surfactants) with first world-scale plant launched in 2024
Acquisitions
-
Bolt-onM&A to strengthen growth businesses
Divestments - Constant portfolio review and exit of commoditized activities
7 | Evonik Company Factbook | 2024
Business transformation:
Strengthening long-term competitiveness of Animal Nutrition business
TODAY
One operating
model for all products within Animal Nutrition
SPECIALTY
NUTRITION | Focus portfolio |
for example | on profitable |
system solutions |
TOMORROW | Running Animal Nutrition with |
two distinct operating models | |
ESSENTIAL Streamlined
NUTRITION operating model
for example
with lean sales
organization
€200 m cost savings by 2025
8 | Evonik Company Factbook | 2024
Business transformation:
Changing hydrogen peroxide portfolio towards specially applications
Success factors
Demand drivers
Ultra-high purity for wafer-cleaning | PAA for waste-water disinfection | PAA / H2O2 for food safety |
▪ Portfolio extension with PeroxyChem into | ▪ Leading PAA supplier in the municipal water | ▪ Solution provider for safe and effective food | ||
dedicated ultra pure electronic-grade H2O2 | treatment industry | disinfectant processing & packaging | ||
▪ Forward integration moving closer to the end | ▪ Improved market access as integrated | ▪ Global capabilities to partner with the leading | ||
customers | solution provider for water treatment | equipment providers of aseptic packaging | ||
▪ Global footprint ensuring reliable supply | solutions | |||
▪ Trend towards smaller electronic device | ▪ Increasing demand for wastewater treatment | ▪ Growing population boosts demand for | ||
geometries | solutions due to demographics and climate | proteins & trend towards packaged food | ||
▪ Increasing number of process steps require | ▪ Tightening regulations require non-toxic, | ▪ Increased focus on sustainable and effective | ||
ultra-high purity agents | environmentally friendly solutions | solutions | ||
9 | Evonik Company Factbook | 2024
Innovation and product mix:
Customer-centric innovation as part of our DNA
Innovation Growth Fields (sales in € m) | Cosmetic Solutions | ||
▪ Expanding portfolio of | |||
innovative active cosmetic | |||
Targeting >€1 bn of sales by 2025 | ingredients | ||
from six Innovation Growth Fields | |||
at above Group margins | Healthcare Solutions | ||
▪ e.g. lipids for mRNA-based | |||
>€650 m | therapies | ||
▪ US production facility under | |||
construction | |||
Membranes | |||
▪ For separation of biogas or | |||
the extraction of hydrogen | |||
2015 2016 2017 2018 2019 2020 2021 2022 2023 | 2025 | ▪ New capacities coming 2025 | |
10 | | Evonik Company Factbook | 2024 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Evonik Industries AG published this content on 15 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 April 2024 08:33:05 UTC.
